

## Change in number of shares and votes in SynAct Pharma AB

**SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 5,191,003 as a result of the directed share issues resolved upon by the extraordinary general meeting on 13 December 2024.**

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 46,487,467.

**For further information, please contact:**

Jeppe Øvlesen, CEO SynAct Pharma

Tel: +45 2844 7567

Email: [JOO@synactpharma.com](mailto:JOO@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: [www.synactpharma.com](http://www.synactpharma.com).

*This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 18:45 CET.*

**Attachments**

[Change in number of shares and votes in SynAct Pharma AB](#)